Cordyceps Sunshine Biotech Holdings Co., Ltd.
RAJAFdata completeness 75%5 fiscal years on filei. The business — what you’d actually own
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $879,3181 | $53,3042 | $882,5333 | $1.25M3 | $1.25M3 |
| Net income | −$491,0064 | −$720,0934 | $751,6095 | −$226,2585 | −$154,8225 |
| Operating cash flow | −$365,3636 | −$321,3786 | $359,7247 | $312,0067 | −$35,8457 |
| Capital expenditure | $100,0008 | $4759 | $319,48710 | $349,23710 | — |
| Free cash flow (derived) | −$465,3636 | −$321,8536 | $40,2377 | −$37,2317 | — |
| Total debt | — | $471,10911 | $431,07911 | — | — |
| Cash & equivalents | $99,68412 | $6,62813 | $23,10413 | $37,28414 | $3,19914 |
| Diluted shares | 100,000 | 104.4M | 111.1M | 111.1M | 111.1M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.05
your share of equity
Profit it earned you last year
−$0.01
Free cash flow it threw off
—
Debt you’d be carrying
—
10 shares is a claim on −$0.05 of net worth that earned you −$0.01 last year.
iii. Is this a good business?
Moat signal · return on equity
— avg · 5y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
+111020% shares · 5y
Share count is up 111020% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 20-F · period ending 2021-12-31 · accession 0001213900-23-039368 (Revenues)
- 20-F/A · period ending 2022-12-31 · accession 0001213900-25-090714 (Revenues)
- 20-F · period ending 2023-12-31 · accession 0001213900-26-057774 (Revenues)
- 20-F/A · period ending 2021-12-31 · accession 0001213900-25-090714 (NetIncomeLoss)
- 20-F · period ending 2023-12-31 · accession 0001213900-26-057774 (NetIncomeLoss)
- 20-F/A · period ending 2021-12-31 · accession 0001213900-25-090714 (NetCashProvidedByUsedInOperatingActivities)
- 20-F · period ending 2023-12-31 · accession 0001213900-26-057774 (NetCashProvidedByUsedInOperatingActivities)
- 20-F/A · period ending 2021-12-31 · accession 0001213900-25-090714 (PaymentsToAcquirePropertyPlantAndEquipment)
- 20-F · period ending 2022-12-31 · accession 0001213900-23-039368 (PaymentsToAcquirePropertyPlantAndEquipment)
- 20-F · period ending 2023-12-31 · accession 0001213900-26-057774 (PaymentsToAcquirePropertyPlantAndEquipment)
- 20-F/A · period ending 2022-12-31 · accession 0001213900-25-090714 (LongTermDebtNoncurrent)
- 20-F · period ending 2021-12-31 · accession 0001213900-23-039368 (CashAndCashEquivalentsAtCarryingValue)
- 20-F/A · period ending 2022-12-31 · accession 0001213900-25-090714 (CashAndCashEquivalentsAtCarryingValue)
- 20-F · period ending 2024-12-31 · accession 0001213900-26-057774 (CashAndCashEquivalentsAtCarryingValue)